Universität zu Köln

van Bremen, Kathrin, Hoffmann, Christian, Mauss, Stefan, Lutz, Thomas, Ingiliz, Patrick, Spinner, Christoph D., Scholten, Stefan, Schwarze-Zander, Carolynne, Berger, Florian, Breitschwerdt, Sven, Schneeweiss, Stephan, Busch, Fabian, Wasmuth, Jan-Christian, Faetkenheuer, Gerd, Lehmann, Clara, Rockstroh, Juergen K. and Boesecke, Christoph (2020). Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection. Liver Int., 40 (12). S. 2978 - 2982. HOBOKEN: WILEY. ISSN 1478-3231

Full text not available from this repository.

Abstract

Several cohorts have shown that long-term tenofovir-containing combination antiretroviral therapy (cART) leads to higher HBsAg seroclearance rates in HIV/HBV coinfected patients vs HBV-monoinfected patients under tenofovir disoproxil fumarate (TDF)-based therapy. We have analysed data on determinants of HBsAg loss in a retrospective multicentric cohort of 359 HIV/HBV coinfected patients. Median CD4 T-cell count at baseline was 359/ul (321-404), CDC stage was C in 20% (n = 70). Most patients (68%) were ART-naive when TDF- or tenofovir alafenamide (TAF)-containing cART was initiated (baseline). After a median follow-up of 11 years HBsAg loss had occurred in 66/359 (18%) patients. However, patients with stage CDC C (P <= .001), lower CD4 gain (P = .043) and not receiving TDF/FTC (P = .008) were less likely to lose HBsAg. Long-term TDF-containing cART appears to achieve higher rates of HBsAg seroclearance compared to published data for HBV monoinfected subjects. However, late presentation for HIV and poor immune recovery significantly impair HBV seroconversion rates.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code van Bremen, Kathrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Mauss, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Lutz, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Ingiliz, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Spinner, Christoph D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Scholten, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwarze-Zander, Carolynne UNSPECIFIED UNSPECIFIED UNSPECIFIED Berger, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Breitschwerdt, Sven UNSPECIFIED UNSPECIFIED UNSPECIFIED Schneeweiss, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Busch, Fabian UNSPECIFIED UNSPECIFIED UNSPECIFIED Wasmuth, Jan-Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, Clara UNSPECIFIED UNSPECIFIED UNSPECIFIED Rockstroh, Juergen K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Boesecke, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-315059
DOI:	10.1111/liv.14684
Journal or Publication Title:	Liver Int.
Volume:	40
Number:	12
Page Range:	S. 2978 - 2982
Date:	2020
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1478-3231
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HEPATITIS-B-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; TENOFOVIR; INFECTION; MORTALITY; COHORT Multiple languages Gastroenterology & Hepatology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/31505